Yahoo Finance

Truist raised the firm’s price target on Zimmer Biomet (ZBH) to $118 from $117 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows. Truist adds that it prefers small-mid size companies over large caps as M&A may be “poised to heat up”.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on ZBH:

• Tesla upgraded, MongoDB initiated: Wall Street’s top analyst calls

• Zimmer Biomet upgraded to Overweight from Neutral at JPMorgan

• Zimmer Biomet receives FDA clearance for OsseoFit Stemless Shoulder System

• Zimmer Biomet price target lowered to $118 from $125 at Barclays

• Citi opens ‘positive catalyst watch’ on Zimmer Biomet